TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9422301
Drug: Atracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 25%
Study: 9422301
Drug: Atracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 75%
Study: 9422301
Drug: Atracurium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 100%
Study: 8272018
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg ASA
Study: 8272018
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ASA
Study: 3305002
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (2 g per day) for 2 weeks in trial 1
Study: 3305002
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (2 g per day) for 4 weeks in trial 2
Study: 28590364
Drug: Bitopertin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitopertin (10 mg)
Study: 23021323
Drug: Implant supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant supported dental restoration in patients with chronic periodontal diseases (Group A)
Study: 10788945
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment for venous leg ulcers
Study: 10788945
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment for pressure ulcers
Study: 8829859
Drug: Ketorolac 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.75 mg.kg-1
Study: 8829859
Drug: Ketorolac 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1.0 mg.kg-1
Study: 8829859
Drug: Ketorolac 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1.5 mg.kg-1
Study: 1340835
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus Metronidazole (TG)
Study: 6367414
Drug: Bepridil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepridil (400 mg once a day)
Study: 30312434
Drug: CTC-positive status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC-positive status 2 years after chemotherapy
Study: 30312434
Drug: CTC-negative status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTC-negative status 2 years after chemotherapy
Study: 26895988
Drug: Gelatine tannate
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatine tannate (250 mg, 4 times/day for children younger than 3 years; 500 mg, 4 times/day for children older than 3 years)
Study: 20151053
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg, 20 mg, 40 mg, or 80 mg based on an algorithm)
Study: 11897771
Drug: ETRA (SB
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETRA (SB 209670) - a dual endothelin type A/endothelin type B receptor antagonist
Study: 10204835
Drug: Glucose (17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (17.5 g)
Study: 10204835
Drug: Aspartame (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (1 g)
Study: 1981996
Drug: Oxatomide gel
Normalized name: oxatomide
DrugBank: Oxatomide (DB12877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxatomide gel at 5% applied twice a day for 14 days
Study: 1981996
Drug: Follow-up without
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up without therapy for 14 days
Study: 465619
Drug: Propranolol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.25 mg/kg body weight)
Study: 24931228
Drug: Aspirin combined
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin combined with mechanical measures
Study: 24931228
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) sodium and rivaroxaban sequentially combined with mechanical measures
Study: 22104610
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of inhaled budesonide twice per day
Study: 12172328
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg / Indapamide 0.625 mg
Study: 12172328
Drug: Perindopril 4
Normalized name: perindopril 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 4 mg / Indapamide 1.25 mg
Study: 7795086
Drug: Oral paste
Normalized name: Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paste and solution containing polymyxin, gentamicin, and nystatin
Study: 7795086
Drug: Placebo paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo paste and solution
Study: 2094065
Drug: Glucose-fructose-xylitol solution
Normalized name: fructose / glucose / phosphoric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-fructose-xylitol solution (GFX-B) - 10.5% solution, infused continuously for 3 days postoperatively
Study: 2094065
Drug: Sole glucose
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole glucose solution (PHY-3) - 10% glucose solution, infused continuously for 3 days postoperatively
Study: 23909742
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate (30 mg.kg(‐1) bolus followed by 10 mg.kg(‐1).h(‐1) continuous infusion)
Study: 21896825
Drug: Mefloquine (MQ)
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefloquine (MQ) 12.5 mg/kg/day for 2 days plus Artesunate (AS) 4.0 mg/kg/day for 3 days
Study: 19839251
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg bid
Study: 10624255
Drug: Homoeopathy treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homoeopathy treatment, details on dosage and duration not available
Study: 8942578
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion at a rate of 4 micrograms.kg‐1.min‐1
Study: 1958393
Drug: Alizapride (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (16 mg/kg) alone
Study: 1958393
Drug: Alizapride (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (16 mg/kg) + Dexamethasone (40 mg)
Study: 1958393
Drug: Metoclopramide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (4 mg/kg) + Dexamethasone (40 mg)
Study: 30104294
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec 100 units/mL (IDeg‐100)
Study: 27159857
Drug: Superpulsed low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superpulsed low level laser therapy (SLLLT) at T0, 24 hours, and 48 hours with a GaAs laser diode
Study: 27159857
Drug: Control site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control site (no SLLLT treatment)
Study: 22894891
Drug: Yoga classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga classes (hatha yoga) held twice a week for 10 weeks
Study: 12685875
Drug: Insulin monotherapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin monotherapy (n = 8)
Study: 12685875
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus glibenclamide (n = 6)
Study: 27306315
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBTuhr)
Study: 15153167
Drug: Azathioprine continued
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine continued treatment
Study: 15153167
Drug: Azathioprine continued
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine continued treatment (dose >1.60 mg/kg/day)
Study: 15153167
Drug: Azathioprine withdrawal
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine withdrawal (dose >1.60 mg/kg/day)
Study: 11485124
Drug: Sulfasalazine 500
Normalized name: sulfasalazine 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine 500 mg tablets twice daily
Study: 7602728
Drug: Vacuum effect
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum effect (change from 40 mL of aspirated air to ≤ 10 mL after 60 mL of air instillation)
Study: 26714972
Drug: Potassium levels
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium levels <3.5 mEq/L
Study: 26714972
Drug: Potassium levels
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium levels ⩾5 mEq/L
Study: 26714972
Drug: Potassium levels
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium levels 3.5 to <4 mEq/L
Study: 26714972
Drug: Potassium levels
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium levels ⩾4.5 mEq/L
Study: 23229850
Drug: Cholestyramine ointment
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholestyramine ointment (15%)
Study: 16645371
Drug: Inhaled Prostacyclin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Prostacyclin (iPGI2)
Study: 16645371
Drug: Intravenous vasodilators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vasodilators (Control)
Study: 16645371
Drug: Inhaled drugs
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled drugs (iNO and iPGI2)
Study: 12540121
Drug: Acid-etch treatment
Normalized name: undecylenic acid Topical Solution [Hongo Killer Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-etch treatment
Study: 8781869
Drug: Caffeine 0
Normalized name: caffeine 0.65 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 0 mg.kg‐1 body mass
Study: 8781869
Drug: Caffeine 5
Normalized name: caffeine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 5 mg.kg‐1 body mass
Study: 8781869
Drug: Caffeine 9
Normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 9 mg.kg‐1 body mass
Study: 1727841
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin) at doses of 1,000 mg/day, 1,250 mg/day, 1,500 mg/day, or 2,000 mg/day for 8 weeks
Study: 1727841
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin) at doses of 1,500 mg and 2,000 mg for older subjects
Study: 1727841
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin)
Study: 6086834
Drug: Comprehensive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive community treatment including a 24-hour crisis service
Study: 6086834
Drug: Comprehensive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive community treatment
Study: 26584896
Drug: Pain Recognition
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Recognition and Treatment (PRT) protocol coupled with basic pain education
Study: 19761871
Drug: Metformin or
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin or Vitamin E
Study: 9805215
Drug: Low-fat ice
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat ice cream (3% fat)
Study: 9805215
Drug: Standard ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ice cream (10% fat)
Study: 3056240
Drug: Clindamycin (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (total dose, 2.4 g) plus Amikacin (total dose, 1 g)
Study: 3056240
Drug: Ticarcillin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticarcillin plus Clavulanic acid (total dose, 20.8 g)
Study: 28911260
Drug: Amiselimod 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiselimod 0.1 mg, 0.2 mg, or 0.4 mg
Study: 28911260
Drug: Amiselimod (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiselimod (various doses)
Study: 17717914
Drug: Strengthening Pi
Normalized name: PI-103
DrugBank: PI-103 (DB17046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthening Pi and activating blood circulation therapy (SPAB)
Study: 17717914
Drug: Indomethacin and
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin and methopterin (Western medicine)
Study: 17717914
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SPAB and Western medicine (CM-WM group)
Study: 15828855
Drug: NuvaRing for
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuvaRing for 21 days plus amoxicillin on days 1‐10
Study: 12097784
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day reinitiated after relapse from placebo
Study: 12097784
Drug: Fluoxetine 40
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 40 mg/day (increased from 20 mg/day)
Study: 12097784
Drug: Fluoxetine 90
Normalized name: fluoxetine 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 90 mg twice a week (increased from 90 mg weekly)
Study: 1979763
Drug: Highly purified
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly purified pork insulin (Actrapid)
Study: 1979763
Drug: Semisynthetic human
Normalized name: INSULIN,NPH,HUMAN/SEMISYNTHETIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semisynthetic human insulin (Actrapid Human)
Study: 34496
Drug: Triazolam (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.6 mg)
Study: 24434301
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of atorvastatin (10 mg daily) or simvastatin (10-20 mg daily)
Study: 21890323
Drug: pONS (carbohydrate-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: pONS (carbohydrate-containing preconditioning oral nutritional supplement enriched with glutamine, antioxidants, and green tea extract)
Study: 19598302
Drug: Probiotic combination
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic combination of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bl‐04
Study: 17599487
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel discontinued more than 6 days before surgery (group 1, n = 35)
Study: 17599487
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel continued until 3 to 5 days before surgery (group 2, n = 51)
Study: 17599487
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel continued within 2 days of surgery (group 3, n = 20)
Study: 15141801
Drug: Remifentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.5 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Study: 15141801
Drug: Remifentanil 1
Normalized name: remifentanil 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Study: 15141801
Drug: Remifentanil 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 1.5 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Study: 11841525
Drug: Intervention arm
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention arm of a trial of the effectiveness of depression treatment
Study: 9823729
Drug: All gel
Normalized name: ALCOHOL 65 mL in 100 mL TOPICAL GEL [Clean All Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All gel formulations
Study: 7714603
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg tirilazad per day intravenously
Study: 7714603
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg tirilazad per day intravenously
Study: 7714603
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg tirilazad per day intravenously
Study: 2468745
Drug: Mitoxantrone (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (14 mg/m2 IV every 3 weeks)
Study: 2468745
Drug: Doxorubicin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (75 mg/m2 IV every 3 weeks)
Study: 31118101
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive intervention (Control)
Study: 28105513
Drug: Ginkgo terpene
Normalized name: terpene resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo terpene lactones meglumine injection (GMI)
Study: 26421861
Drug: Cognitive-Behavioral Prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Prevention (CBP) program consisting of 8 weekly 90-minute group sessions followed by 6 monthly continuation sessions.
Study: 15285777
Drug: Levodopa (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (200 mg as Sinemet)
Study: 11103753
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion for 6 hours
Study: 11103753
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion with valsartan pretreatment
Study: 1449046
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg x 3) for three months
Study: 1449046
Drug: Acipimox (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (after three months treatment)
Study: 1449046
Drug: Acipimox (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (before treatment)
Study: 16834838
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 100 mg once daily
Study: 16834838
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 200 mg once daily
Study: 16834838
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 300 mg once daily
Study: 16834838
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 400 mg once daily
Study: 12768357
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of 100 mg regular-release (rr) and 100 mg sustained-release (sr) L-dopa/benserazide
Study: 12768357
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of 100 mg regular-release (rr) and 100 mg sustained-release (sr) L-dopa/benserazide after 4 weeks
Study: 10671905
Drug: Milnacipran 12.5
Normalized name: milnacipran 12.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 12.5 mg, 25 mg, 50 mg, 100 mg (single dose)
Study: 10671905
Drug: Milnacipran 75
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milnacipran 75 mg (50 mg + 25 mg) per day
Study: 10671905
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg (25 mg + 25 mg) per day
Study: 9176040
Drug: Urodilatin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urodilatin infusion (20 ng min‐1 kg‐1)
Study: 9176040
Drug: Urodilatin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urodilatin infusion (40 ng min‐1 kg‐1)
Study: 8260563
Drug: Methylphenidate (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (optimal drug dosage)
Study: 3910338
Drug: 0.2% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% NaF solution rinse every fortnight
Study: 22012149
Drug: Weekly Monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly Monitoring Control
Study: 1685166
Drug: Shortwave diathermy
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shortwave diathermy and exercise therapy
Study: 7139526
Drug: Local radiation
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local radiation with or without chemotherapy
Study: 28944412
Drug: Split-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose regimen (all solutions)
Study: 28944412
Drug: Single-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose regimen (all solutions)
Study: 21111555
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin (target INR 2 to 3)
Study: 21111555
Drug: Fixed-dose ximelagatran
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose ximelagatran 36 mg twice daily
Study: 17288690
Drug: Erythropoietic protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietic protein therapy
Study: 15044883
Drug: Simethicone (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone (80 mg)
Study: 15044883
Drug: No supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: No supplemental medication
Study: 3243093
Drug: Cefaclor thrice
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor thrice daily
Study: 24169612
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl added to guideline-recommended treatment including inhibitors of the renin-angiotensin-aldosterone system